GLP-3 Reta

Reta is a tri-agonist peptide analog investigated for activity across GLP-1, GIP, and GCG (glucagon) receptor pathways. Researchers use Reta to explore multi-receptor signaling, metabolic modeling, and peptide optimization under controlled conditions.

How does Reta work?

Research shows that Retatrutide functions as a triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways, resulting in comprehensive metabolic modulation.

Activation of GLP-1 receptors reduces appetite, delays gastric emptying, and improves glycemic control. GIP receptor engagement further enhances insulin sensitivity and lipid metabolism. Meanwhile, glucagon receptor stimulation increases basal energy expenditure and promotes fat oxidation.

Collectively, these mechanisms induce metabolic reprogramming, leading to sustained reductions in total and visceral fat. Early clinical trials demonstrate that Retatrutide achieves greater fat and weight loss than both Semaglutide and Tirzepatide, particularly in reducing central (visceral) fat stores.

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE. NOT FOR HUMAN CONSUMPTION.